By targeting CDK7, it was, for instance, possible to selectively target cancers with high oncogene dependence, such as T-cell acute lymphoblastic leukemia (T-ALL) reliant on the oncogenic transcription factor Runt-related transcription factor 1 (RUNX1) [225], MYC-driven cancers, and triple-negative breast cancer [226]. The gene discussed is RUNX1; the disease is triple-negative breast carcinoma.